NCT01804686 2026-04-13
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
Clinical Trials
16 trialsNCT05963074 2026-04-13
TAILOR
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06136559 2026-04-13
BELLWAVE-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06299540 2026-04-13
QOLIBRI
Janssen Cilag S.A.S.
Recruiting
NCT05254743 2026-04-01
BRUIN-CLL-314
Eli Lilly and Company
Phase 3 Recruiting
NCT03331198 2026-03-04
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Juno Therapeutics, a Subsidiary of Celgene
Phase 1/2 Recruiting
NCT07052695 2025-12-15
Mosunetuzumab for CLL MRD Clearance
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06958705 2025-11-25
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT03128879 2025-11-21
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06520098 2025-10-14
Benefit VA
VA Office of Research and Development
Phase 2 Recruiting
NCT04494503 2025-04-16
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
Phase 1/2 Recruiting
NCT05694312 2023-12-01
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Recruiting
NCT04758975 2023-10-04
VALUABLE
IRCCS San Raffaele
Phase 2 Recruiting
NCT04908228 2023-10-03
FIGHT
IRCCS San Raffaele
Phase 2 Recruiting
NCT04771507 2021-02-25
IbruOnOff
Karolinska University Hospital
Phase 1/2 Recruiting
NCT03980002 2019-06-10
BDHCLL001
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting